Leinco Technologies

Anti-Human IRF8 (CT)

Product Code:
 
LEI-I-508
Product Group:
 
Primary Antibodies
Host Type:
 
Rabbit
Antibody Clonality:
 
Polyclonal
Regulatory Status:
 
RUO
Target Species:
 
Human
Application:
 
Western Blot (WB)
Shipping:
 
Ambient
Storage:
 
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-I-508-20ug20 ug£199.00
Quantity:
LEI-I-508-0.1mg0.1 mg£591.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:I-520
Long Description:
Interferons (IFN)s are involved in a multitude of immune interactions during viral infections and play a major role in both the induction and regulation of innate and adaptive antiviral mechanisms (1 for review). During infection, host-virus interactions signal downstream molecules such as transcription factors such as IFN regulatory factor-3 (IRF3) which can act to stimulate transcription of IFN-α/β genes. Unlike IRF3, IRF8 appears to act as a negative regulator of IFN-induced genes in most cases,2,3 but IRF8 mediates activation of NF-κB by the toll-like receptor 9 (TLR9) after stimulation by unmethylated CpG DNA in dendritic cells.4 Finally, it has been shown that IRF8 decreases bcl-2 expression and thus may play a role in chronic myelogenous leukemia.
Target:
IRF8

References

1. Malmgaard, L. (2004) J. Interferon & Cyto. Res. 24:439 2. Weisz, A. et al. (1992) J. Biol. Chem. 267:25589 3. Nelson, N. et al. (1993) Mol. Cell. Biol. 13:588 4. Tsujimura, H. et al. (2004) J. Immunol. 172:6820